Atención farmacéutica en el paciente oncológicoestudio de las interacciones con antineoplásicos orales y adecuación multidisciplinar del tratamiento

  1. Lara Martín Rizo
Supervised by:
  1. Irene Iglesias Peinado Director
  2. María Pilar Gómez Serranillos Cuadrado Director

Defence university: Universidad Complutense de Madrid

Year of defence: 2021

  1. Juana Benedí González Chair
  2. Paloma Bermejo-Bescós Secretary
  3. Fernando de Jesús Franco Committee member
  4. Pablo Veiga Herreros Committee member
  5. Mercedes González Gomis Committee member
  1. Farmacología, Farmacognosia y Botánica

Type: Thesis


Cancer is the universal name for a large group of disease, defined as an uncontrolled proliferation of abnormal cells, and invasion of the body by spreading to nearby or distant organs or tissues. Chemotherapy is the main treatment for cancer and benefits patients in the form of decreased relapse and metastasis and longer overall survival.The expansion of oral chemotherapy has grown exponentially. The oral administration introduces the possibility of interactions related to absorption and improper co-administration with other drugs, issues that are not critical when using intravenous chemotherapy. For patients, using such agents is attractive partly because of perceived greater convenience. However, the use of many of these agents presents multiple challenges, including novel toxicity profiles, increases risk for drug interactions, high cost, and potential challenges with treatment adherence. Knowledge and the proper management of drug interactions can improve the safety and effectiveness of treatments. The studies carried out present disparate methodologies, so the incidence of interactions, their severity and risk reduction strategies are poorly defined. Pharmacy services are essential in preventing adverse effects and potential interactions in cancer patients. The principal objective is to describe the potential interactions, pharmacokinetic and pharmacodynamic, between oral antineoplastic agents and concomitant medication. The second objective is to carry out a pharmaceutical intervention on the potential interactions detected to analyze the influence of the early detection of interactions...